RGC — Regencell Bioscience Holdings Cashflow Statement
0.000.00%
Last trade - 00:00- $797.04m
- $789.08m
- 41
- 21
- 80
- 44
Annual cashflow statement for Regencell Bioscience Holdings, fiscal year end - June 30th, USD millions except per share, conversion factor applied.
2020 June 30th | 2021 June 30th | 2022 June 30th | 2023 June 30th | 2024 June 30th | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | PROSPECTUS/A | 20-F | 20-F | 20-F | 20-F |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -0.812 | -1.35 | -7.59 | -6.06 | -4.36 |
| Depreciation | |||||
| Non-Cash Items | — | — | 3.21 | 1.4 | 0.889 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | 0.076 | 0.553 | -1.03 | -0.594 | -0.833 |
| Change in Prepaid Expenses | |||||
| Change in Other Assets | |||||
| Change in Accounts Payable | |||||
| Change in Accrued Expenses | |||||
| Other Operating Cash Flow | |||||
| Cash from Operating Activities | -0.727 | -0.767 | -5.27 | -4.96 | -4 |
| Capital Expenditures | -0.118 | 0 | -0.781 | -0.027 | -0.005 |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | — | — | -10 | 0.086 | 5.25 |
| Sale of Fixed Assets | |||||
| Sale/Maturity of Investment | |||||
| Purchase of Investments | |||||
| Cash from Investing Activities | -0.118 | 0 | -10.8 | 0.059 | 5.24 |
| Financing Cash Flow Items | 0.988 | -0.172 | 0.164 | 0.135 | 0.102 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 0.988 | 0.44 | 22.4 | 0.135 | 0.102 |
| Foreign Exchange Effects | |||||
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 0.144 | -0.328 | 6.36 | -4.85 | 1.4 |